NO165201C - Fremgangsmaate for fremstilling av hybrid humanleukocyttinterferoner paa 165-166 aminosyrer omfattende en subsekvens fra human leukocytt-interferon a og en subsekvens fra human leukocytt-interferon b eller d. - Google Patents

Fremgangsmaate for fremstilling av hybrid humanleukocyttinterferoner paa 165-166 aminosyrer omfattende en subsekvens fra human leukocytt-interferon a og en subsekvens fra human leukocytt-interferon b eller d.

Info

Publication number
NO165201C
NO165201C NO813785A NO813785A NO165201C NO 165201 C NO165201 C NO 165201C NO 813785 A NO813785 A NO 813785A NO 813785 A NO813785 A NO 813785A NO 165201 C NO165201 C NO 165201C
Authority
NO
Norway
Prior art keywords
leukocyt
human
interferon
interferons
subsequence
Prior art date
Application number
NO813785A
Other languages
English (en)
Norwegian (no)
Other versions
NO813785L (no
NO165201B (no
Inventor
David Van Norman Goeddel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/237,388 external-priority patent/US4414150A/en
Priority claimed from US06/305,657 external-priority patent/US4456748A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO813785L publication Critical patent/NO813785L/no
Priority to NO871589A priority Critical patent/NO165555C/no
Publication of NO165201B publication Critical patent/NO165201B/no
Publication of NO165201C publication Critical patent/NO165201C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO813785A 1980-11-10 1981-11-09 Fremgangsmaate for fremstilling av hybrid humanleukocyttinterferoner paa 165-166 aminosyrer omfattende en subsekvens fra human leukocytt-interferon a og en subsekvens fra human leukocytt-interferon b eller d. NO165201C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO871589A NO165555C (no) 1980-11-10 1987-04-14 Kunstig hybrid humant leukocytt-interferon-kodende dna-sekvens.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20557980A 1980-11-10 1980-11-10
US06/237,388 US4414150A (en) 1980-11-10 1981-02-23 Hybrid human leukocyte interferons
US06/305,657 US4456748A (en) 1981-02-23 1981-09-25 Hybrid human leukocyte interferons

Publications (3)

Publication Number Publication Date
NO813785L NO813785L (no) 1982-05-11
NO165201B NO165201B (no) 1990-10-01
NO165201C true NO165201C (no) 1991-01-16

Family

ID=27394813

Family Applications (1)

Application Number Title Priority Date Filing Date
NO813785A NO165201C (no) 1980-11-10 1981-11-09 Fremgangsmaate for fremstilling av hybrid humanleukocyttinterferoner paa 165-166 aminosyrer omfattende en subsekvens fra human leukocytt-interferon a og en subsekvens fra human leukocytt-interferon b eller d.

Country Status (34)

Country Link
EP (1) EP0051873B1 (de)
JP (1) JP2642291B2 (de)
KR (1) KR920007439B1 (de)
AT (1) ATE46718T1 (de)
AU (1) AU555293B2 (de)
BR (1) BR8107293A (de)
CA (2) CA1212915A (de)
CH (2) CH663032A5 (de)
DE (2) DE3144469A1 (de)
DK (1) DK173590B1 (de)
DO (1) DOP1981004064A (de)
DZ (1) DZ350A1 (de)
ES (2) ES506955A0 (de)
FI (1) FI79550C (de)
FR (1) FR2493867B1 (de)
GB (1) GB2090258B (de)
GR (1) GR81947B (de)
HK (1) HK51685A (de)
IE (1) IE51850B1 (de)
IL (1) IL64243A (de)
IT (1) IT1169276B (de)
KE (1) KE3536A (de)
LU (1) LU83745A1 (de)
MC (1) MC1424A1 (de)
MY (2) MY8700710A (de)
NL (1) NL189092C (de)
NO (1) NO165201C (de)
NZ (1) NZ198906A (de)
PH (1) PH18565A (de)
PL (1) PL233748A1 (de)
PT (1) PT73955B (de)
SE (1) SE460539B (de)
YU (1) YU46597B (de)
ZW (1) ZW26981A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
WO1983000693A1 (en) * 1981-08-14 1983-03-03 Berg, Kurt, Frimann SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES
EP0072541A3 (de) * 1981-08-14 1984-04-18 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Menschliche Leukozyten-Interferone, Verfahren zu deren Mikrobiologischer Herstellung, Zwischenprodukte und diese enthaltende Zusammensetzungen
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
EP0098876A1 (de) * 1982-01-19 1984-01-25 Cetus Corporation Hybrid-interferone verschiedener klassen
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
CA1252046A (en) * 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
US4751287A (en) * 1983-02-24 1988-06-14 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr Human leukocyte interferon N and a method of producing same in bacterial cells
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
US4892743A (en) * 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
JPS6156199A (ja) * 1984-08-27 1986-03-20 Shionogi & Co Ltd 新規ヒトインタ−フエロンα類
EP0173935A1 (de) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid-Lymphoblastoid-Leukozyten-Humaninterferone
DE3434345A1 (de) * 1984-09-19 1986-03-27 Hoechst Ag, 6230 Frankfurt Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
EP0194006B1 (de) * 1985-02-01 1992-04-29 Imperial Chemical Industries Plc Analoge Interferon-Polypeptide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE78262T1 (de) * 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
EP0240550A4 (de) * 1985-09-26 1989-09-19 Genetics Inst Lungen-oberflachenaktive proteine.
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
EP0490233A1 (de) * 1986-03-10 1992-06-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Monoclonale Antikörper gegen BgIII-Hybridinterferone, deren Verwendung und Verfahren zu ihrer Herstellung
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
GB2273931A (en) * 1992-09-28 1994-07-06 Unilever Plc Mutant polypeptides
CA2223088A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7318918B2 (en) 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032134B2 (de) * 1980-01-08 1993-10-13 Biogen, Inc. DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von dem menschlichen Interferon-alpha ähnlichen Polypeptiden

Also Published As

Publication number Publication date
JP2642291B2 (ja) 1997-08-20
GB2090258A (en) 1982-07-07
KR920007439B1 (ko) 1992-09-01
SE460539B (sv) 1989-10-23
ES8302778A1 (es) 1983-02-01
IE51850B1 (en) 1987-04-15
DE3144469A1 (de) 1982-09-02
ZW26981A1 (en) 1982-06-02
CA1277616C (en) 1990-12-11
CH663032A5 (de) 1987-11-13
IT8124967A0 (it) 1981-11-10
EP0051873A2 (de) 1982-05-19
MY8700710A (en) 1987-12-31
DK494681A (da) 1982-05-11
PH18565A (en) 1985-08-09
DZ350A1 (fr) 2004-09-13
MC1424A1 (fr) 1982-10-18
IT1169276B (it) 1987-05-27
NO813785L (no) 1982-05-11
EP0051873B1 (de) 1989-09-27
HK51685A (en) 1985-07-12
ES506955A0 (es) 1983-02-01
DOP1981004064A (es) 1988-03-16
FR2493867A1 (fr) 1982-05-14
NO165201B (no) 1990-10-01
IL64243A0 (en) 1982-02-28
PL233748A1 (en) 1983-07-18
YU46597B (sh) 1994-01-20
YU265681A (en) 1984-08-31
KE3536A (en) 1985-06-07
IL64243A (en) 1985-11-29
NL8105078A (nl) 1982-06-01
KR830007825A (ko) 1983-11-07
PT73955A (en) 1981-12-01
NL189092B (nl) 1992-08-03
ES8304200A1 (es) 1983-03-01
FI813539L (fi) 1982-05-11
CA1212915A (en) 1986-10-21
EP0051873A3 (en) 1982-09-22
FI79550B (fi) 1989-09-29
FR2493867B1 (fr) 1986-06-27
MY8800066A (en) 1988-12-31
NL189092C (nl) 1993-01-04
NZ198906A (en) 1985-12-13
FI79550C (fi) 1990-01-10
GR81947B (de) 1984-12-12
CH660743A5 (de) 1987-06-15
LU83745A1 (de) 1983-09-01
IE812622L (en) 1982-05-10
AU7730481A (en) 1982-05-20
GB2090258B (en) 1984-05-02
ES512354A0 (es) 1983-03-01
DK173590B1 (da) 2001-04-02
BR8107293A (pt) 1982-08-03
PT73955B (en) 1983-11-23
AU555293B2 (en) 1986-09-18
SE8106641L (sv) 1982-06-24
DE3177106D1 (en) 1989-11-02
ATE46718T1 (de) 1989-10-15
JPH07308191A (ja) 1995-11-28

Similar Documents

Publication Publication Date Title
NO165201C (no) Fremgangsmaate for fremstilling av hybrid humanleukocyttinterferoner paa 165-166 aminosyrer omfattende en subsekvens fra human leukocytt-interferon a og en subsekvens fra human leukocytt-interferon b eller d.
SE8105657L (sv) Mikrobiell framstellning av humanfibroblastinterferon
HK49285A (en) Interferons and process for their preparation
ES499262A0 (es) Procedimiento para la obtencion de un microorganismo que forma un polipetido con la secuencia de aminoacidos del inter- feron de leucocitos humanos.
ATE159297T1 (de) Expression von menschlichen serumalbumin in methylotrophischen hefen
DE3584579D1 (de) Herstellung von polypeptiden mit human-gammainterferon-aktivitaet.
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
EP0072541A3 (de) Menschliche Leukozyten-Interferone, Verfahren zu deren Mikrobiologischer Herstellung, Zwischenprodukte und diese enthaltende Zusammensetzungen
DE59108128D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN NOVEMBER 2001